ArriVent Biopharma Showcases Global Oncology Pipeline and Late-Stage Firmonertinib Program in New Presentation

Reuters11-11

ArriVent Biopharma Showcases Global Oncology Pipeline and Late-Stage Firmonertinib Program in New Presentation

ArriVent Biopharma Inc. has outlined updates on its global oncology pipeline, highlighting its lead program, firmonertinib, which has received Breakthrough Therapy Designation for first-line treatment of EGFR Exon 20 insertion mutant non-small cell lung cancer (NSCLC). The company expects topline results from a registrational study in early 2026 and is expanding firmonertinib into a pivotal trial for first-line EGFR PACC mutant NSCLC, supported by positive clinical data. ArriVent is also advancing its next-generation antibody-drug conjugate $(ADC)$ portfolio, with ARR-217 currently in Phase 1 trials for gastrointestinal tumors and additional ADC programs expected to enter clinical development in 2026. The pipeline includes multiple programs in various stages targeting solid tumors and NSCLC, with global development efforts outside China. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582671793?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582671793","market":"us","top_or_hot":-1,"title":"ArriVent Biopharma Showcases Global Oncology Pipeline and Late-Stage Firmonertinib Program in New Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ArriVent Biopharma Showcases Global Oncology Pipeline and Late-Stage Firmonertinib Program in New Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ArriVent Biopharma Inc. has outlined updates on its global oncology pipeline, highlighting its lead program, firmonertinib, which has received Breakthrough Therapy Designation for first-line treatment of EGFR Exon 20 insertion mutant non-small cell lung cancer (NSCLC). The company expects topline results from a registrational study in early 2026 and is expanding firmonertinib into a pivotal trial for first-line EGFR PACC mutant NSCLC, supported by positive clinical data. ArriVent is also advancing its next-generation antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> portfolio, with ARR-217 currently in Phase 1 trials for gastrointestinal tumors and additional ADC programs expected to enter clinical development in 2026. The pipeline includes multiple programs in various stages targeting solid tumors and NSCLC, with global development efforts outside China. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ArriVent Biopharma Showcases Global Oncology Pipeline and Late-Stage Firmonertinib Program in New Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArriVent Biopharma Showcases Global Oncology Pipeline and Late-Stage Firmonertinib Program in New Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ArriVent Biopharma Showcases Global Oncology Pipeline and Late-Stage Firmonertinib Program in New Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ArriVent Biopharma Inc. has outlined updates on its global oncology pipeline, highlighting its lead program, firmonertinib, which has received Breakthrough Therapy Designation for first-line treatment of EGFR Exon 20 insertion mutant non-small cell lung cancer (NSCLC). The company expects topline results from a registrational study in early 2026 and is expanding firmonertinib into a pivotal trial for first-line EGFR PACC mutant NSCLC, supported by positive clinical data. ArriVent is also advancing its next-generation antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> portfolio, with ARR-217 currently in Phase 1 trials for gastrointestinal tumors and additional ADC programs expected to enter clinical development in 2026. The pipeline includes multiple programs in various stages targeting solid tumors and NSCLC, with global development efforts outside China. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDLc2DYDJ:1","article_id":"2582671793","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582671793","pubTimestamp":1762871941,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ArriVent Biopharma Inc. has outlined updates on its global oncology pipeline, highlighting its lead program, firmonertinib, which has received Breakthrough Therapy Designation for first-line treatment of EGFR Exon 20 insertion mutant non-small cell lung cancer . The company expects topline results from a registrational study in early 2026 and is expanding firmonertinib into a pivotal trial for first-line EGFR PACC mutant NSCLC, supported by positive clinical data. ArriVent is also advancing its next-generation antibody-drug conjugate  portfolio, with ARR-217 currently in Phase 1 trials for gastrointestinal tumors and additional ADC programs expected to enter clinical development in 2026. The pipeline includes multiple programs in various stages targeting solid tumors and NSCLC, with global development efforts outside China. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AVBP":"ArriVent BioPharma"},"translate_title":"ArriVent Biopharma在新演示中展示了全球肿瘤产品线和后期Firmonertinib项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVBP":0.9},"content_text":"ArriVent Biopharma Showcases Global Oncology Pipeline and Late-Stage Firmonertinib Program in New Presentation\n    \n\n        ArriVent Biopharma Inc. has outlined updates on its global oncology pipeline, highlighting its lead program, firmonertinib, which has received Breakthrough Therapy Designation for first-line treatment of EGFR Exon 20 insertion mutant non-small cell lung cancer (NSCLC). The company expects topline results from a registrational study in early 2026 and is expanding firmonertinib into a pivotal trial for first-line EGFR PACC mutant NSCLC, supported by positive clinical data. ArriVent is also advancing its next-generation antibody-drug conjugate $(ADC)$ portfolio, with ARR-217 currently in Phase 1 trials for gastrointestinal tumors and additional ADC programs expected to enter clinical development in 2026. The pipeline includes multiple programs in various stages targeting solid tumors and NSCLC, with global development efforts outside China. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582671793","isCrawlerRequest":true}